Literature DB >> 30396892

Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Patrick M Meyer Sauteur1,2,3,4, Adrianus C J M de Bruijn1, Catarina Graça1, Anne P Tio-Gillen5,6, Silvia C Estevão1, Theo Hoogenboezem1, Rudi W Hendriks7, Christoph Berger3,4, Bart C Jacobs5,6, Annemarie M C van Rossum2, Ruth Huizinga5, Wendy W J Unger8.   

Abstract

Antibody responses to Mycoplasma pneumoniae correlate with pulmonary M. pneumoniae clearance. However, M. pneumoniae-specific IgG antibodies can cross-react with the myelin glycolipid galactocerebroside (GalC) and cause neurological disorders. We assessed whether antiglycolipid antibody formation is part of the physiological immune response to M. pneumoniae We show that antibodies against M. pneumoniae proteins and glycolipids arise in serum of M. pneumoniae-infected children and mice. Although antibodies to M. pneumoniae glycolipids were mainly IgG, anti-GalC antibodies were only IgM. B-1a cells, shown to aid in protection against pathogen-derived glycolipids, are lacking in Bruton tyrosine kinase (Btk)-deficient mice. M. pneumoniae-infected Btk-deficient mice developed M. pneumoniae-specific IgG responses to M. pneumoniae proteins but not to M. pneumoniae glycolipids, including GalC. The equal recovery from M. pneumoniae infection in Btk-deficient and wild-type mice suggests that pulmonary M. pneumoniae clearance is predominantly mediated by IgG reactive with M. pneumoniae proteins and that M. pneumoniae glycolipid-specific IgG or IgM is not essential. These data will guide the development of M. pneumoniae-targeting vaccines that avoid the induction of neurotoxic antibodies.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Bruton tyrosine kinase; Guillain-Barré syndrome; Mycoplasma pneumoniaezzm321990; antibodies; autoimmunity; encephalitis; galactocerebroside; molecular mimicry; pneumonia; vaccine

Mesh:

Substances:

Year:  2019        PMID: 30396892      PMCID: PMC6346122          DOI: 10.1128/IAI.00663-18

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Differential susceptibility to Mycoplasma pulmonis intranasal infection in X-linked immunodeficient (xid), severe combined immunodeficient (scid), and immunocompetent mice.

Authors:  K Sandstedt; A Berglöf; R Feinstein; G Bölske; B Evengård; C I Smith
Journal:  Clin Exp Immunol       Date:  1997-06       Impact factor: 4.330

2.  B cell-deficient muMT mice as an experimental model for Mycoplasma infections in X-linked agammaglobulinemia.

Authors:  A Berglöf; K Sandstedt; R Feinstein; G Bölske; C I Smith
Journal:  Eur J Immunol       Date:  1997-08       Impact factor: 5.532

3.  Mycoplasma pneumoniae infections in volunteers.

Authors:  C B Smith; R M Chanock; W T Friedewald; R H Alford
Journal:  Ann N Y Acad Sci       Date:  1967-07-28       Impact factor: 5.691

4.  Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage.

Authors:  R W Hendriks; M F de Bruijn; A Maas; G M Dingjan; A Karis; F Grosveld
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

5.  The Role of B Cells in Carriage and Clearance of Mycoplasma pneumoniae From the Respiratory Tract of Mice.

Authors:  Patrick M Meyer Sauteur; Ruben C A de Groot; Silvia C Estevão; Theo Hoogenboezem; Adrianus C J M de Bruijn; Marcel Sluijter; Marjolein J W de Bruijn; Ismé M De Kleer; Rien van Haperen; Judith M A van den Brand; Debby Bogaert; Pieter L A Fraaij; Cornelis Vink; Rudi W Hendriks; Janneke N Samsom; Wendy W J Unger; Annemarie M C van Rossum
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

6.  Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization.

Authors:  N Cimolai; A C Cheong; B J Morrison; G P Taylor
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

Review 7.  Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions--Systematic review and meta-analysis.

Authors:  Inbal Linchevski; Eyal Klement; Eyal Klmenet; Ran Nir-Paz
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

8.  Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia.

Authors:  C M Roifman; C P Rao; H M Lederman; S Lavi; P Quinn; E W Gelfand
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

9.  Role of IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae.

Authors:  Satoshi Kurata; Takako Osaki; Hideo Yonezawa; Ken Arae; Haruhiko Taguchi; Shigeru Kamiya
Journal:  BMC Microbiol       Date:  2014-06-13       Impact factor: 3.605

10.  Nodal marginal zone B cells in mice: a novel subset with dormant self-reactivity.

Authors:  Anna-Karin E Palm; Heike C Friedrich; Sandra Kleinau
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

View more
  4 in total

Review 1.  Mycoplasma pneumoniae Infections and Primary Immune Deficiencies.

Authors:  Dimitri Poddighe; Erkan Demirkaya; Vitaliy Sazonov; Micol Romano
Journal:  Int J Clin Pract       Date:  2022-07-08       Impact factor: 3.149

Review 2.  Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development.

Authors:  Zhulin Jiang; Shuihong Li; Cuiming Zhu; Runjie Zhou; Polly H M Leung
Journal:  Pathogens       Date:  2021-01-25

Review 3.  A Breakdown of Immune Tolerance in the Cerebellum.

Authors:  Christiane S Hampe; Hiroshi Mitoma
Journal:  Brain Sci       Date:  2022-02-28

Review 4.  Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2020-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.